Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy
Yixue Han1, Ruiqi Wang2, Lina Tian3
1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China.
Abstract:
Cyclin-dependent kinase 9 (CDK9), a key member of the CDK family, plays a crucial role in transcriptional regulation. As its expression is dysregulated in various cancers, CDK9 is regarded as a promising therapeutic target. However, the clinical efficacy of traditional CDK9 inhibitors is limited by potential on-target toxicity, and degradation-based strategies face similar challenges. In recent years, dual-target inhibitors against CDK9 have gradually become a research focus. Our group previously reported a CDK9/EZH2 dual inhibitor, D16, though its activity still required further improvement. Furthermore, to validate the general applicability of this design strategy, we designed a series of new CDK9/EZH2 dual-target inhibitors by conjugating a self-designed CDK9-targeting fragment with a selective EZH2 inhibitor. Among them, compound A9 demonstrated excellent inhibitory activity, with IC50 values of 19.3 nM in U2932 cells and 9.1 nM in KARPAS-422 cells. Compared to single-target inhibitors, its dual inhibitory action significantly increased the apoptosis rate and induced substantial DNA damage in DLBCL cells.
Insights
New dual-target inhibitors combining Cyclin-dependent kinase 9 (CDK9) and EZH2 inhibition show promise for cancer therapy. Compound A9 effectively targets cancer cells, increasing apoptosis and DNA damage compared to single-target drugs.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Cyclin-dependent kinase 9 (CDK9) is vital for transcription and a cancer therapeutic target.
- Existing CDK9 inhibitors face limitations due to toxicity and efficacy.
- Dual-targeting strategies offer a novel approach to overcome these challenges.
Purpose of the Study:
- To design and evaluate novel dual-target inhibitors of CDK9 and EZH2.
- To validate the efficacy of a dual-inhibition strategy in cancer cells.
- To improve upon previous dual-inhibitor designs.
Main Methods:
- Conjugation of a novel CDK9-targeting fragment with a selective EZH2 inhibitor.
- Synthesis of a series of new dual-target inhibitors.
- In vitro testing of compound efficacy (IC50 values) and biological effects (apoptosis, DNA damage) in cancer cell lines.
Main Results:
- Compound A9 exhibited potent dual inhibitory activity against CDK9/EZH2.
- A9 showed strong efficacy in U2932 (19.3 nM) and KARPAS-422 (9.1 nM) cells.
- Dual inhibition significantly enhanced cancer cell apoptosis and induced DNA damage in DLBCL cells compared to single-target inhibitors.
Conclusions:
- The developed CDK9/EZH2 dual inhibitors represent a promising therapeutic strategy.
- Compound A9 demonstrates superior efficacy over single-target agents.
- This dual-targeting approach holds potential for improved cancer treatment outcomes.
Related Concept Videos
01:26Drug Discovery: Overview
01:29Pharmacogenomics: Identification of New Drug Targets
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...